never had an issue with CEO salary that was vestedin except this company REALLY stands out like a sore thumb.
all the cheerleaders are hoping, yes please wait, yes MC will go up, blah blah, the SP does not lie after 4 years, any value by strategic would have been picked up long ago the low skin in the game, etc, etc TIME FOR A CHANGE. this management should be quietly set aside to save the $1.8m salary and other 6 figure salaries from other executives (this is not large pharma) and use the share holder money into the clinical/regulatory trials streams for accelerating FDA approved asap when SP will finally increase exponentially at this inflexion point and meanwhile whynot hire a part time CEO med tech guy/lady on a lower salary and give them plenty of share options to manage this process until we get here, cannot see that harming SP
Watchthisspace tweet, page-91
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |